Evidence map›Paper›PMID 40956618›Full record

ArticleJCI insight2025

In utero rescue of neurological dysfunction in a mouse model of Wiedemann-Steiner syndrome.

Tinna Reynisdottir, Kimberley J Anderson, Katrin Möller, Stefán Pétursson, Andrew Brinn, Katheryn P Franklin, Juan Ouyang, Asbjorg O Snorradottir, Cathleen M Lutz, Aamir R Zuberi and 2 more

Abstract read
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tinna ReynisdottirLouma G. Laboratory of Epigenetic Research, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Kimberley J AndersonLouma G. Laboratory of Epigenetic Research, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Katrin MöllerLouma G. Laboratory of Epigenetic Research, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Stefán PéturssonLouma G. Laboratory of Epigenetic Research, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Andrew BrinnDepartment of Anthropology, University of Florida, Gainesville, USA.
Katheryn P FranklinDepartment of Anthropology, University of Florida, Gainesville, USA.
Juan OuyangLouma G. Laboratory of Epigenetic Research, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Asbjorg O SnorradottirFaculty of Medicine, University of Iceland, Reykjavik, Iceland.
Cathleen M LutzThe Jackson Laboratory, Bar Harbor, Maine, USA.
Aamir R ZuberiThe Jackson Laboratory, Bar Harbor, Maine, USA.
Valerie B DeLeonDepartment of Anthropology, University of Florida, Gainesville, USA.
Hans T BjornssonLouma G. Laboratory of Epigenetic Research, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

Funding

The Jackson Laboratory Center for Precision GeneticsU54OD030187 · OD · JACKSON LABORATORY · PI Cathleen M Lutz · 2020 to 2026
$17.2M
NIH HHS U54 OD030187
6 · The paper itself

Abstract

Wiedemann-Steiner syndrome (WDSTS) is a rare genetic cause of intellectual disability that is primarily caused by heterozygous loss-of-function variants in the gene encoding the histone lysine methyltransferase 2A (KMT2A). Prior studies have shown successful postnatal amelioration of disease phenotypes for Rett, Rubinstein-Taybi, and Kabuki syndromes, which are related Mendelian disorders of the epigenetic machinery. To explore whether the neurological phenotype in WDSTS is treatable in utero, we created a mouse model carrying a loss-of-function variant placed between 2 loxP sites. Kmt2a+/LSL mice demonstrated core features of WDSTS including growth retardation, craniofacial abnormalities, and hypertrichosis as well as hippocampal memory defects. The neurological phenotypes were rescued upon restoration of KMT2A in utero following breeding to a nestin-Cre. Together, our data provide a mouse model to explore the potential therapeutic window in WDSTS. Our work suggests that WDSTS has a window of opportunity extending at least until the midpoint of in utero development, making WDSTS an ideal candidate for future therapeutic strategies.

Indexed as

Abnormalities, MultipleHistone-Lysine N-MethyltransferaseIntellectual DisabilityMyeloid-Lymphoid Leukemia ProteinAnimalsCraniofacial AbnormalitiesDisease Models, AnimalFemaleHumansHypertrichosisLoss of Function MutationMaleMiceMice, TransgenicPhenotypePregnancyHistone-Lysine N-MethyltransferaseKmt2a protein, mouseMyeloid-Lymphoid Leukemia ProteinEpigeneticsGeneticsIntellectual disabilityNeurodevelopmentNeuroscience

Identifiers

PMID40956618
PMCPMC12581663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.